Skip to main content

Table 3 Anti-MCV, anti-CCP, and IgM-RF at baseline and after 6 and 12 months of infliximab therapy

From: Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy

  Response
6 months
Baseline 6 months Response
12 months
Baseline 12 months
Anti-MCV, U/mL Responders
(n = 11)
654 (89–2,918) 535 (56–3,000) Responders
(n = 15)
293 (61–2,918) 117a (48–3,582)
  Nonresponders
(n = 12)
307 (60–1,145) 227 (40–1,234) Nonresponders
(n = 8)
363 (60–1,145) 227 (47–1,500)
Anti-CCP, U/mL Responders
(n = 11)
1,402 (83–11,360) 1,300 (54–11,370) Responders
(n = 15)
1,246 (83–11,360) 837b (48–12,640)
  Nonresponders
(n = 12)
962 (130–4,232) 1,134 (74–2,392) Nonresponders
(n = 8)
1,169 (275–4,232) 1,331 (126–4,313)
IgM-RF, IU/mL Responders
(n = 11)
91.5 (10–424) 58 (10–216) Responders
(n = 15)
74.5 (9–781) 49.5c (10–214)
  Nonresponders
(n = 12)
205 (9–949) 133c (10–367) Nonresponders
(n = 8)
283 (14–949) 152c (35–463)
  1. Values are expressed as median (range), and the nonparametric Wilcoxon signed rank test was used for paired comparisons of changes in anti-CCP and anti-MCV titres between responders and nonresponders. aP < 0.01 versus baseline; bP < 0.05 versus baseline; cP = 0.02 versus baseline. Anti-CCP, anti-cyclic citrullinated peptide antibody; anti-MCV, anti-mutated vimentin citrullinated antibody; RF, rheumatoid factor.